bullish
Humanised CAR Tregs are a key step forward
SUMMARY
TxCell has announced it has a promising humanised CAR-Treg product that can be developed to control graft rejection in solid organ transplant. A trial is planned to start in late 2018. CAR Tregs offer a powerful and versatile new approach to immune system disorders; multiple sclerosis, lupus nephritis and the skin disorder bullous pemphigoid are also targets. TxCell had cash of €8.68m on 30 June. The indicative market cap has been rebased onto CAR Treg indications and is now €84.4m, formerly €74m.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- Loading...
x